arrow_back Civic Audit
Share share

Boosting US Drug & Medical Device Production: Tax Credits & Transparency

This act aims to increase the domestic manufacturing of drugs, pharmaceutical ingredients, and medical devices in the United States. It introduces tax credits for companies producing these items in economically distressed areas, potentially creating jobs and improving the availability of critical medical products. Additionally, it enhances transparency and coordination in drug quality inspection processes to prevent shortages.
Key points
Companies manufacturing drugs, pharmaceutical ingredients, and medical devices in the U.S. may receive tax credits, especially if operating in high-poverty areas.
Increased transparency and better coordination in drug quality inspections by government agencies to help prevent drug shortages.
Support for the development of new drug manufacturing technologies to make processes more efficient and resilient to disruptions.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_S_2082
Sponsor: Sen. Scott, Tim [R-SC]
Process start date: 2021-06-16